Healthcare Analytical Testing Services Market

Healthcare Analytical Testing Services Market Size by Type (Biomarker Testing, Stability Testing, Raw Material Testing, Batch-release Testing, Cleaning Validation), End User (Pharmaceutical Companies, Medical Device Companies) & Region - Global Forecast to 2029

Report Code: AST 4341 Apr, 2024, by marketsandmarkets.com

The global size of healthcare analytical testing services market in terms of revenue was estimated to be worth $7.4 billion in 2024 and is poised to reach $12.6 billion by 2029, growing at a CAGR of 11.2% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. This notable growth driven by various factors.

The growing market for healthcare analytical testing services is driven by various factors. There is a rising demand across industries for services ensuring quality assurance and regulatory compliance. Additionally, the pursuit of precise analytical techniques presents opportunities for service providers, while governmental initiatives support investment and innovation. These efforts collectively contribute to the global expansion of the market. Moreover, outsourcing strategies driven by cost-effectiveness and the evolving pharmaceutical landscape further stimulate market growth. Additionally, expanding into new markets amplifies the need for tailored testing solutions, thereby increasing demand for healthcare analytical testing services. The evolving regulatory landscape, the imperative to avoid impractical investments, and the necessity to minimize the risk of product recalls are significant drivers for the Healthcare analytical testing services market.

Healthcare Analytical Testing Services Market Size, Dynamics & Ecosystem

Healthcare Analytical Testing Services Market Size, Dynamics & Ecosystem

To know about the assumptions considered for the study, Request for Free Sample Report

Healthcare analytical testing services Industry Dynamics

Driver: Changing regulatory landscape and the increasing complexity of products to drive the market

The growth of the market in healthcare is propelled by changing regulatory mandates and the increasing complexity of healthcare products. Regulatory agencies enforce stringent standards for pharmaceuticals, medical devices, and other healthcare products, necessitating comprehensive testing to ensure compliance. Additionally, advancements in medical technology have led to the development of complex drugs, biologics, and medical devices, requiring sophisticated analytical techniques for characterization and quality assurance. These factors drive the demand for healthcare analytical testing services in the healthcare industry, contributing to market growth.

Rising number of Clinical Trials

The rise in clinical trials is a significant driver behind the growth of the market. As pharmaceutical, biopharmaceutical, and medical device companies continue to innovate and develop new products, the demand for healthcare analytical testing services surges. Clinical trials are crucial stages in the development and approval process of new drugs and medical devices. These trials require rigorous testing to ensure safety, efficacy, and regulatory compliance. Healthcare analytical testing services play a pivotal role in conducting various tests, including bioanalytical, pharmacokinetic, and biomarker testing, among others. The increasing number of clinical trials globally, fueled by advancements in medical research and the quest for novel treatments, directly translates to a higher demand for healthcare analytical testing services. Moreover, the complexity of clinical trial designs and the stringent regulatory requirements further accentuate the need for specialized testing capabilities, driving the growth of the market.

Restraint: Lack of skilled professionals

The lack of skilled professionals poses a significant challenge that could hamper market growth for market. As demand for testing services continues to rise across various industries, including pharmaceuticals, food and beverage, and environmental testing, there is a growing need for trained personnel proficient in operating Analytical testing equipment and interpreting analytical results accurately. However, the shortage of skilled professionals in this field can hinder the growth of the market, leading to delays in research and development activities, quality control processes, and regulatory compliance efforts. Addressing this skills gap through training programs, educational initiatives, and talent development strategies will be essential to overcome this obstacle and sustain market growth for market.

Opportunity: Harnessing Government Support and Technology Advancements in Healthcare analytical testing services

Supportive government initiatives, coupled with the increasing adaptability to Software as a Service (SaaS) and outcome-based software technology, present significant opportunities for the market in healthcare. Government funding programs, tax incentives, and regulatory reforms aimed at improving healthcare infrastructure and research capabilities drive investment in healthcare analytical testing services, ensuring compliance and quality control. The adoption of SaaS models enables smaller laboratories and healthcare facilities to access advanced analytical capabilities cost-effectively, enhancing efficiency and data management practices. Additionally, outcome-based software technology delivers measurable results and value by providing predictive analytics and customized recommendations, optimizing decision-making processes. Collectively, these trends empower healthcare organizations to leverage sophisticated analytical tools, streamline workflows, and deliver better outcomes for patients and stakeholders, driving the growth of the market.

Challenge: Need for improvement to the sensitivity of analytical testing

The need for improvement in sensitivity of bioanalytical methods poses a significant challenge for the pharmaceutical industry. With the development of new chemical entities (NCEs) that are increasingly potent and effective, there is growing pressure to detect drug substances and their metabolites with greater sensitivity. This demand is further compounded by the exploration of unconventional chemical classes for highly potent therapeutics. Bioanalytical scientists are tasked with supporting early-stage in vivo work by generating high-quality data within shorter timeframes. However, meeting the sensitivity requirements for new and challenging compounds administered at very low levels can be daunting. It often necessitates extensive sample preparation, such as solid-phase or liquid-liquid extraction, as well as complex chromatography techniques like two-dimensional or trap-and-elute liquid chromatography. While automation can streamline the time required for these processes, the development of appropriate methods remains time-consuming, especially given the tight timelines typically faced by bioanalytical departments.

Healthcare Analytical Testing Services Market Segmentation & Geographical Spread

Healthcare Analytical Testing Services Market Segmentation & Geographical Spread

To know about the assumptions considered for the study, download the pdf brochure

The Healthcare analytical testing services Market ecosystem comprises entities responsible for the end-to-end workflow of analytical testing types and services. The major stakeholders present in this market include Analytical testing service providers, pharmaceutical, biopharmaceutical, and biotechnology companies, food and beverage industry, environment protection and forensic institutes, clinicians, researchers, hospitals, and clinics, and medical device companies. The service providers in the industry continue to enhance and mature their offerings to add value.

The Healthcare analytical testing services industry, is projected to grow at a CAGR of 11.2% between 2024 and 2029.”

The Healthcare analytical testing services market is projected to reach USD 12.6 billion by 2029 from USD 7.4 billion in 2023, at a CAGR of 11.2% during the forecast period. The rising preference to outsource testing, stringent regulatory requirements, increase in clinical trials and rising R & D investments are driving the growth of this market.

Biohealthcare analytical testing services segment accounted for a substantial share of the Healthcare analytical testing services industry, by type in 2023.”

The dominance of the biohealthcare analytical testing services segment in the healthcare analytical testing services market stems from its comprehensive range of services tailored to various drug types, such as vaccines, small molecules, and biologics. These services play a crucial role in ensuring the safety, efficacy, and quality of pharmaceutical products. By offering extensive bioanalytical testing solutions, including assays for drug quantification, metabolite identification, and pharmacokinetic analysis, this segment meets the diverse needs of pharmaceutical companies across the drug development process. Additionally, advancements in analytical techniques and technologies have enabled the segment to enhance its capabilities, further solidifying its position as a key player in the market.

Cell based Assay segment accounted for a considerable share in the Healthcare analytical testing services industry, by type of bioanalytical testing in 2023

The segmentation of the healthcare analytical testing services market based on type includes various categories such as cell-based assays, virology testing, biomarker testing, immunogenicity and neutralizing antibody testing, pharmacokinetic testing, and other biohealthcare analytical testing services. In 2023, the cell-based assays segment emerged as the dominant force within the market. This prominence can be attributed to the increasing adoption of cell-based assays in high-throughput screening applications. Unlike biochemical assays, cell-based assays offer the advantage of providing more relevant in vivo biological information, thereby accelerating the drug discovery process. This preference for cell-based assays reflects the industry's recognition of their efficacy in evaluating compound efficacy, toxicity, and other crucial parameters during preclinical studies. Consequently, pharmaceutical companies and research organizations are increasingly relying on cell-based assays to streamline their drug development efforts and enhance their chances of success in bringing novel therapeutics to market.

Pharmaceutical and biopharmaceutical companies have accounted for the largest share in Healthcare analytical testing services industry by end user in 2023

In the healthcare analytical testing services market, pharmaceutical and biopharmaceutical companies stood out as the major contributors, holding the largest share. This dominance stems from several factors related to the segment's unique needs and operational strategies. The market segmentation, based on end users, includes pharmaceutical and biopharmaceutical companies, medical device companies, forensic labs, hospitals and clinics, cosmetics and nutraceutical companies. Among these, pharmaceutical and biopharmaceutical companies emerged as the primary stakeholders, capturing the largest share in 2023. This significant market presence can be attributed to the growing trend among these companies to outsource healthcare analytical testing services. By outsourcing these services, pharmaceutical and biopharmaceutical firms aim to optimize their profit margins and concentrate on their core competencies, such as research, development, and commercialization of innovative drugs and therapies. Outsourcing analytical testing allows these companies to leverage the specialized expertise and advanced technologies offered by third-party service providers, enabling them to streamline operations, expedite time-to-market for new products, and ensure compliance with stringent regulatory standards. Thus, the substantial market share held by pharmaceutical and biopharmaceutical companies underscores the critical role of healthcare analytical testing services in supporting their overall business objectives and facilitating the delivery of safe, efficacious, and high-quality healthcare products to patients worldwide.

North America dominated the Healthcare analytical testing services industry in 2023

Prominent players in the Healthcare analytical testing services market include The prominent players in the global market include Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK), Thermo Fisher Scientific, Inc. (US), Pace Analytical Services LLC (US), Intertek Group plc (UK), IQVIA Inc. (US), Merck KGaA (Germany), Source BioScience (UK), Almac Group (UK), ICON Plc (Ireland), Frontage Laboratories, Inc. (US), STERIS Plc (US), Sartorius AG (Germany), ALS Life Science (US), Syneos Health, INC (US), Medpace Holdings, Inc. (US), LGC Limited (UK), Parexel International Corporation (US), Celerion (US). Pharmaron (China), and BioAgilytix Labs (US).

Scope of the Healthcare Analytical Testing Services Industry

Report Metric

Details

Market Revenue in 2024

$7.4 billion

Projected Revenue by 2029

$12.6 billion

Revenue Rate

Poised to Grow at a CAGR of 11.2%

Market Driver

Changing regulatory landscape and the increasing complexity of products to drive the market

Market Opportunity

Harnessing Government Support and Technology Advancements in Healthcare analytical testing services

The study categorizes the healthcare analytical testing services market to forecast revenue and analyze trends in each of the following submarkets

By Type

  • Bioanalytical Testing Services
    • Pharmacokinetic & Toxicokinetic Testing
    • Immunogenicity & Neutralizing Antibody Testing
    • Biomarker Testing
    • Bioassays
    • Other Bioanalytical Testing Services
  • Physical Characterization Services
    • Laser Particle Size Analysis
    • Thermal Analysis
    • Optical Characterization
    • Surface Area Analysis
    • Other Physical Characterization Analysis Services
  • Method Development & Validation Services
    • Extractable/Leachables Method Development & Validation
    • Process Impurity Method Development & Validation
    • Stability-Indicating Method Validation
    • Cleaning Validation
    • Analytical Standard Characterization
    • Technical Consulting
    • Other Method Development & Validation Services
  • Raw Material Testing Services
    • Complete Compendial Testing
    • Container Testing
    • Heavy Metal Testing
    • Water Content Analysis
    • Other Raw Material Testing Services
  • Batch-Release Testing Services
    • Dissolution Testing
    • Elemental Impurity Testing
    • Disintegration Testing
    • Hardness Testing
    • Friability Testing
    • Other Batch-Release Testing Services
  • Stability Testing Services
    • Drug Substance Stability Testing
    • Formulation Evaluation Stability Testing
    • Accelerated Stability Testing
    • Photostability Testing
    • Foreced Degradation Testing
    • Other Stability Testing Services
  • Microbial Testing Services
    • Microbial Limit Testing
    • Virology Testing
    • Sterility Testing
    • Endotoxin Testing
    • Preservative Efficacy Testing
    • Other Microbial Testing Services
  • Geonimics Testing Services
  • Other Analytical Testing Services*
  • (*Other Analytical Testing includes, Clinical Chemistry Testing Services, Nutritional Analysis Testing, Clinical Diagnostics Testing)

By End User

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Medical Device Companies
  • Hospitals And Clinics
  • Forensic Labs
  • Cosmetics & Nutraceuticals Companies

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • Italy
    • Spain
    • France
    • RoE
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • Rest of Middle East and Africa

Recent Developments of Healthcare Analytical Testing Services Industry:

  • In March 2024, Thermo Fisher Scientific Inc. (US), collaborated with Symphogen (US), to provide biopharmaceutical discovery and development laboratories with innovative tools and streamlined workflows for efficient characterization of complex therapeutic proteins
  • In February 2024, Charles River Laboratories (US) partnered with Wheeler Bio, Inc. (US). This agreement accelerates the transition from preclinical to early clinical stages for biotech firms, streamlining processes and providing a comprehensive solutions.
  • In May 2023, Laboratory Corporation of America Holdings (US Collaborated with Forge Biologics (US) to advance gene therapy development and manufacturing. This collaboration aims to expedite clinical timelines, overcome analytical development barriers, and address regulatory hurdles associated with manufacturing and development processes.
  • In May 2023, SGS S.A. (Switzerland), SGS SA acquired a majority stake in Nutrasource Pharmaceutical and Nutraceutical Services Inc.(Canada0), Initially acquiring 60% of Nutrasource's shares, SGS also has the option to acquire the remaining 40% in 2026. This strategic acquisition strengthens SGS's presence in key market segments and enhances its ability to deliver comprehensive services to clients worldwide.
  • In July 2022, Eurofins Scientific (Luxembourg), acquired WESSLING (Hungary), to strengthen its presence in Central and Eastern Europe and to enhance its BioPharma Product Testing capabilities.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 50)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
           1.2.2 MARKET SEGMENTATION
                    FIGURE 1 MARKETS COVERED
           1.2.3 REGIONS COVERED
                    FIGURE 2 REGIONAL SEGMENTATION
           1.2.4 YEARS CONSIDERED
    1.3 CURRENCY CONSIDERED 
    1.4 LIMITATIONS 
           1.4.1 METHODOLOGY-RELATED LIMITATIONS
           1.4.2 SCOPE-RELATED LIMITATIONS
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 56)
    2.1 RESEARCH DATA 
    2.2 RESEARCH METHODOLOGY DESIGN 
          FIGURE 3 RESEARCH DESIGN
           2.2.1 SECONDARY RESEARCH
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    FIGURE 4 PRIMARY SOURCES
                    2.2.2.1 Key data from primary sources
                    2.2.2.2 Insights from primary experts
                               FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                               FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION METHODOLOGY 
          FIGURE 7 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 8 REVENUE SHARE ANALYSIS: COMPANY ILLUSTRATION
          FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION
          FIGURE 10 TOP-DOWN APPROACH
          FIGURE 11 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          FIGURE 12 CAGR PROJECTIONS
    2.4 DATA TRIANGULATION PROCEDURE 
          FIGURE 13 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE ESTIMATION 
    2.6 STUDY ASSUMPTIONS 
    2.7 RISK ASSESSMENT 
          TABLE 1 RISK ASSESSMENT ANALYSIS
    2.8 RECESSION IMPACT ANALYSIS 
 
3 EXECUTIVE SUMMARY (Page No. - 70)
    FIGURE 14 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
    FIGURE 15 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
    FIGURE 16 PHYSICAL CHARACTERIZATION TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
    FIGURE 17 MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    FIGURE 18 GEOGRAPHICAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 75)
    4.1 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET OVERVIEW 
          FIGURE 19 GROWING ADOPTION OF OUTSOURCED ANALYTICAL TESTING SERVICES BY PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES TO DRIVE GROWTH
    4.2 EUROPE: MARKET, BY TYPE AND COUNTRY (2023) 
          FIGURE 20 BIOANALYTICAL TESTING SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2023
    4.3 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 21 CHINA, INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
    4.4 REGIONAL MIX: MARKET (2022–2029) 
          FIGURE 22 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD (2022–2029)
    4.5 MARKET: DEVELOPED VS. EMERGING ECONOMIES (2024 VS. 2029) 
          FIGURE 23 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 80)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 24 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Stringent regulatory guidelines
                    5.2.1.2 Growing focus on analytical testing of biologics & biosimilars
                                TABLE 2 PATENT EXPIRY OF BEST-SELLING BIOLOGICS
                    5.2.1.3 Increasing outsourcing of analytical testing by pharmaceutical & medical device companies
                    5.2.1.4 Increasing number of clinical trials
                                FIGURE 25 INCREASING NUMBER OF CLINICAL TRIALS WORLDWIDE (2004–2024)
                                FIGURE 26 PERCENTAGE OF REGISTERED STUDIES BY LOCATION (AS OF MARCH 08, 2024)
                    5.2.1.5 Growing R&D expenditure in pharmaceutical & biopharmaceutical industry
                                FIGURE 27 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2002–2022
                    5.2.1.6 Rising acceptance of quality-by-design approach in pharmaceutical research & manufacturing
                                TABLE 3 IMPACT ANALYSIS: DRIVERS
           5.2.2 RESTRAINTS
                    5.2.2.1 Increasing pressure on market players due to rising costs and market competition
                                TABLE 4 IMPACT ANALYSIS: RESTRAINTS
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Adoption of new techniques and technologies
                    5.2.3.2 Growing focus on emerging economies
                                TABLE 5 IMPACT ANALYSIS: OPPORTUNITIES
           5.2.4 CHALLENGES
                    5.2.4.1 Shortage of skilled professionals
                    5.2.4.2 Specific requirements for innovative formulations and medical devices
                    5.2.4.3 Need to improve sensitivity of bioanalytical methods
                                TABLE 6 IMPACT ANALYSIS: CHALLENGES
    5.3 ECOSYSTEM ANALYSIS 
          TABLE 7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ROLE IN ECOSYSTEM
          FIGURE 28 MARKET: ECOSYSTEM ANALYSIS
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 29 VALUE CHAIN ANALYSIS
    5.5 CASE STUDY ANALYSIS 
           5.5.1 UNLOCKING BIOPHARMACEUTICAL DEVELOPMENT POTENTIAL THROUGH OUTSOURCING ANALYTICAL TESTING
           5.5.2 REVOLUTIONIZING PHARMACEUTICAL TESTING: A CASE STUDY IN ANALYTICAL TESTING EVOLUTION
    5.6 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 8 PORTER’S FIVE FORCES ANALYSIS
          FIGURE 30 PORTER’S FIVE FORCES ANALYSIS: MARKET
           5.6.1 THREAT OF NEW ENTRANTS
           5.6.2 BARGAINING POWER OF SUPPLIERS
           5.6.3 INTENSITY OF COMPETITIVE RIVALRY
           5.6.4 BARGAINING POWER OF BUYERS
           5.6.5 THREAT OF SUBSTITUTES
    5.7 REGULATORY LANDSCAPE 
           5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 13 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.7.2 REGULATORY ANALYSIS
                    TABLE 14 ICH QUALITY GUIDELINES FOR PHARMACEUTICAL GMPS
                    TABLE 15 OVERVIEW OF GUIDELINES OF LABORATORY SERVICES
           5.7.3 NORTH AMERICA
           5.7.4 EUROPE
                    TABLE 16 DEVELOPMENT OF GLP ACROSS COUNTRIES
                    TABLE 17 REGULATORY AUTHORITIES AND LAUNCH OF GLP MONITORING PROGRAMS IN EUROPEAN COUNTRIES
           5.7.5 ASIA PACIFIC
    5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 31 REVENUE SHIFT AND NEW POCKETS: MARKET
    5.9 KEY CONFERENCES & EVENTS, 2024–2025 
          TABLE 18 HEALTHCARE ANALYTICAL TESTING MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.10 INVESTMENT AND FUNDING SCENARIO 
           FIGURE 32 NUMBER OF INVESTOR DEALS IN MARKET, BY KEY PLAYER, 2018–2022
           FIGURE 33 VALUE OF INVESTOR DEALS IN MARKET, BY KEY PLAYER, 2018-2022
    5.11 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
                      FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
                      TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
           5.11.2 BUYING CRITERIA
                      FIGURE 35 KEY BUYING CRITERIA FOR END USERS
                      TABLE 20 KEY BUYING CRITERIA FOR END USERS
 
6 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE (Page No. - 106)
    6.1 INTRODUCTION 
          TABLE 21 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
    6.2 BIOANALYTICAL TESTING 
          TABLE 22 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 23 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.2.1 PHARMACOKINETIC & TOXICOKINETIC TESTING
                    6.2.1.1 Increasing number of clinical trials for drug development to propel growth
                                TABLE 24 PHARMACOKINETIC TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.2.2 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING
                    6.2.2.1 Increasing requirement for drug safety approvals to support market growth
                                TABLE 25 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.2.3 BIOMARKER TESTING
                    6.2.3.1 Rising need for specialized drug development to drive market
                                TABLE 26 BIOMARKER TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.2.4 BIOASSAY TESTING
                    6.2.4.1 Growing adoption of high-content screening for cytotoxicity testing to fuel growth
                                TABLE 27 BIOASSAY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.2.5 OTHER BIOANALYTICAL TESTING SERVICES
                    TABLE 28 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
    6.3 PHYSICAL CHARACTERIZATION 
          TABLE 29 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 30 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.3.1 LASER PARTICLE SIZE ANALYSIS
                    6.3.1.1 Growing importance of particle size analysis in manufacturing pharmaceutical dosage forms to drive market
                                TABLE 31 LASER PARTICLE SIZE ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.3.2 THERMAL ANALYSIS
                    6.3.2.1 Advancements in thermal analysis techniques to support growth
                                TABLE 32 THERMAL ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.3.3 OPTICAL CHARACTERIZATION
                    6.3.3.1 Growing complexity of biological structures to contribute to growth
                                TABLE 33 OPTICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.3.4 SURFACE AREA ANALYSIS
                    6.3.4.1 Growing need for surface analysis to streamline drug development processes to fuel growth
                                TABLE 34 SURFACE AREA ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.3.5 OTHER PHYSICAL CHARACTERIZATION SERVICES
                   TABLE 35 OTHER PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
    6.4 METHOD DEVELOPMENT & VALIDATION 
          TABLE 36 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 37 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.4.1 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION
                    6.4.1.1 Growing development of parenterally administered drugs and biologic products to drive market
                                TABLE 38 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.4.2 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION
                    6.4.2.1 Rising emphasis on impurity testing to boost market
                                TABLE 39 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.4.3 STABILITY-INDICATING METHOD VALIDATION
                    6.4.3.1 Need to ensure safety and efficacy of therapeutic drugs to spur growth
                                TABLE 40 STABILITY-INDICATING METHOD VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.4.4 CLEANING VALIDATION & METHOD DEVELOPMENT
                    6.4.4.1 Growing needs to evaluate cleaning practices and ensure complete decontamination to fuel growth
                                TABLE 41 CLEANING VALIDATION & METHOD DEVELOPMENT SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.4.5 ANALYTICAL STANDARD CHARACTERIZATION
                    6.4.5.1 Growing importance of analytical standard characterization in drug development to support market
                                TABLE 42 ANALYTICAL STANDARD CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.4.6 TECHNICAL CONSULTING
                    6.4.6.1 Need for regulatory approvals for drug development to drive market
                                TABLE 43 TECHNICAL CONSULTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.4.7 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES
                    TABLE 44 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
    6.5 RAW MATERIAL TESTING 
          TABLE 45 RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 46 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.5.1 COMPLETE COMPENDIAL TESTING
                    6.5.1.1 Need to determine efficacy and safety of therapeutic products to drive growth
                                TABLE 47 COMPLETE COMPENDIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.5.2 CONTAINER TESTING
                    6.5.2.1 Need to optimize sealing and evaluate temperature impact to fuel growth
                                TABLE 48 CONTAINER TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.5.3 HEAVY METAL TESTING
                    6.5.3.1 Implementation of various techniques and technologies for heavy metal testing to aid growth
                                TABLE 49 HEAVY METAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.5.4 WATER CONTENT ANALYSIS
                    6.5.4.1 Need to check for water content in pharmaceutical products to support growth
                                TABLE 50 WATER CONTENT ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.5.5 OTHER RAW MATERIAL TESTING SERVICES
                    TABLE 51 OTHER RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
    6.6 BATCH-RELEASE TESTING SERVICES 
          TABLE 52 BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 53 BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.6.1 DISSOLUTION TESTING
                    6.6.1.1 Wide usage of dissolution testing in formulation development and manufacturing to drive growth
                                TABLE 54 DISSOLUTION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.6.2 ELEMENTAL IMPURITY TESTING
                    6.6.2.1 Need to minimize cost of in-house analysis and labor to fuel growth
                                TABLE 55 ELEMENTAL IMPURITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.6.3 DISINTEGRATION TESTING
                    6.6.3.1 Need to ensure batch-to-batch consistency of pharmaceutical dosage forms to promote growth
                                TABLE 56 BREAKDOWN OF DISINTEGRATION METHODS AND IMMERSION MEDIA
                                TABLE 57 DISINTEGRATION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.6.4 HARDNESS TESTING
                    6.6.4.1 Need to assess manufacturability and compactness of pharmaceutical formulations to ensure growth
                                TABLE 58 HARDNESS TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.6.5 FRIABILITY TESTING
                    6.6.5.1 Need to measure resistance of                                 TABLEts and granules to abrasion or fracture to support market
                                TABLE 59 FRIABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.6.6 OTHER BATCH-RELEASE TESTING SERVICES
                    TABLE 60 OTHER BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
    6.7 STABILITY TESTING 
          TABLE 61 STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 62 STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.7.1 DRUG SUBSTANCE STABILITY TESTING
                    6.7.1.1 Regulatory requirements for drug approval to drive market
                                TABLE 63 DRUG SUBSTANCE STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.7.2 FORMULATION EVALUATION STABILITY TESTING
                    6.7.2.1 Need to analyze and predict shelf life of products to drive demand
                                TABLE 64 FORMULATION EVALUATION STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.7.3 ACCELERATED STABILITY TESTING
                    6.7.3.1 Growing use of accelerated stability testing to determine shelf life of pharmaceutical products to fuel growth
                                TABLE 65 ACCELERATED STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.7.4 PHOTOSTABILITY TESTING
                    6.7.4.1 Need for robust photostability testing process to ensure product quality and safety to drive adoption
                                TABLE 66 PHOTOSTABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.7.5 FORCED DEGRADATION TESTING
                    6.7.5.1 Regulatory requirements and need for comprehensive stability testing in pharmaceutical industry to boost market
                                TABLE 67 FORCED DEGRADATION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.7.6 OTHER STABILITY TESTING SERVICES
                    TABLE 68 OTHER STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
    6.8 MICROBIAL TESTING 
          TABLE 69 MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 70 MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.8.1 MICROBIAL LIMIT TESTING
                    6.8.1.1 Need to determine whether products comply with compendial specifications for microbial quality to boost adoption
                                TABLE 71 STANDARD LIMITS FOR MICROBIAL LIMIT TESTING
                                TABLE 72 MICROBIAL LIMIT TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.8.2 VIROLOGY TESTING
                    6.8.2.1 Increasing outbreaks of viral diseases to drive market
                                TABLE 73 VIROLOGY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.8.3 STERILITY TESTING
                    6.8.3.1 Rising development of parenteral preparations and immunological products to drive market
                                TABLE 74 STERILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.8.4 ENDOTOXIN TESTING
                    6.8.4.1 Need to standardize procedures and follow regulatory guidelines to support demand
                                TABLE 75 ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.8.5 PRESERVATIVE EFFICACY TESTING
                    6.8.5.1 Need to ensure product safety for product approval to support growth
                                TABLE 76 PRESERVATIVE EFFICACY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.8.6 OTHER MICROBIAL TESTING SERVICES
                    TABLE 77 OTHER MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
    6.9 GENOMIC TESTING SERVICES 
           6.9.1 NEED TO GAIN INSIGHTS INTO DISEASE MECHANISMS AND TREATMENT RESPONSES TO BOOST MARKET
                    TABLE 78 GENOMIC TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
    6.1 OTHER ANALYTICAL TESTING SERVICES 
          TABLE 79 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
 
7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER (Page No. - 157)
    7.1 INTRODUCTION 
          TABLE 80 MARKET, BY END USER, 2022–2029 (USD MILLION)
    7.2 PHARMACEUTICAL COMPANIES 
           7.2.1 INCREASED OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH
                    FIGURE 36 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2020–2022
                    TABLE 81 MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
    7.3 BIOPHARMACEUTICAL COMPANIES 
           7.3.1 GROWING INVESTMENTS IN BIOPHARMACEUTICAL COMPANIES TO BOOST MARKET GROWTH
                    TABLE 82 MARKET FOR BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
    7.4 MEDICAL DEVICE COMPANIES 
           7.4.1 STRICT APPROVAL NORMS FOR MEDICAL DEVICES TO SUPPORT GROWTH
                    TABLE 83 MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022–2029 (USD MILLION)
    7.5 HOSPITALS & CLINICS 
           7.5.1 GROWING PREVALENCE OF CHRONIC DISEASES TO FAVOR MARKET GROWTH
                    TABLE 84 MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)
    7.6 FORENSIC LABS 
           7.6.1 GROWING USE OF ANALYTICAL TESTING IN FORENSIC LABS TO BOOST MARKET GROWTH
                    TABLE 85 MARKET FOR FORENSIC LABS, BY REGION, 2022–2029 (USD MILLION)
    7.7 COSMETIC & NUTRACEUTICAL COMPANIES 
           7.7.1 STRINGENT GUIDELINES FOR QUALITY CONTROL TO DRIVE MARKET
                    TABLE 86 MARKET FOR COSMETIC & NUTRACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
 
8 HEALTHCARE ANALYTICAL TESTING MARKET, BY REGION (Page No. - 166)
    8.1 INTRODUCTION 
          FIGURE 37 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC SNAPSHOT
          TABLE 87 MARKET, BY REGION, 2022–2029 (USD MILLION)
    8.2 NORTH AMERICA 
           8.2.1 NORTH AMERICA: RECESSION IMPACT
                    FIGURE 38 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
                    TABLE 88 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 89 NORTH AMERICA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 90 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 91 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 92 NORTH AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 93 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 94 NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 95 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 96 NORTH AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 97 NORTH AMERICA: MARKET, BY END USER, 2022–2029 (USD MILLION)
           8.2.2 US
                    8.2.2.1 High number of pre-registration drugs in pipeline to drive market
                                FIGURE 39 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2021)
                                TABLE 98 US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 99 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 100 US: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 101 US: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 102 US: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 103 US: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 104 US: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 105 US: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.2.3 CANADA
                    8.2.3.1 Presence of well-established CROs to support market growth
                                FIGURE 40 CANADA: ONGOING CLINICAL TRIALS, BY THERAPEUTIC AREA (2023)
                                TABLE 106 CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 107 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 108 CANADA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 109 CANADA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 110 CANADA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 111 CANADA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 112 CANADA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 113 CANADA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
    8.3 EUROPE 
           8.3.1 EUROPE: RECESSION IMPACT
                    TABLE 114 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 115 EUROPE: MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 116 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 117 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 118 EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 119 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 120 EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 121 EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 122 EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 123 EUROPE: MARKET, BY END USER, 2022–2029 (USD MILLION)
           8.3.2 GERMANY
                    8.3.2.1 Government support and flexible labor laws make Germany favorable location for clinical trials
                                TABLE 124 GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 125 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 126 GERMANY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 127 GERMANY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 128 GERMANY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 129 GERMANY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 130 GERMANY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 131 GERMANY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.3.3 FRANCE
                    8.3.3.1 Favorable government regulations to drive market
                                TABLE 132 FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 133 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 134 FRANCE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 135 FRANCE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 136 FRANCE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 137 FRANCE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 138 FRANCE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 139 FRANCE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.3.4 UK
                    8.3.4.1 Investments by pharmaceutical sponsors for drug discovery services to support growth
                                TABLE 140 UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 141 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 142 UK: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 143 UK: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 144 UK: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 145 UK: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 146 UK: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 147 UK: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.3.5 ITALY
                    8.3.5.1 Low drug approval time to support market growth
                                TABLE 148 ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 149 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 150 ITALY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 151 ITALY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 152 ITALY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 153 ITALY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 154 ITALY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 155 ITALY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.3.6 SWITZERLAND
                    8.3.6.1 Large and growing pharma production volume to drive demand for analytical testing services
                                TABLE 156 SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 157 SWITZERLAND: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 158 SWITZERLAND: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 159 SWITZERLAND: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 160 SWITZERLAND: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 161 SWITZERLAND: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 162 SWITZERLAND: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 163 SWITZERLAND: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.3.7 SPAIN
                    8.3.7.1 Rising R&D expenditure to boost growth
                                TABLE 164 SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 165 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 166 SPAIN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 167 SPAIN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 168 SPAIN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 169 SPAIN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 170 SPAIN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 171 SPAIN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.3.8 REST OF EUROPE
                    TABLE 172 REST OF EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 173 REST OF EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 174 REST OF EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 175 REST OF EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 176 REST OF EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 177 REST OF EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 178 REST OF EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 179 REST OF EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
    8.4 ASIA PACIFIC 
           8.4.1 ASIA PACIFIC: RECESSION IMPACT
                    FIGURE 41 ASIA PACIFIC: HEALTHCARE ANALYTICS TESTING SERVICES MARKET SNAPSHOT
                    TABLE 180 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 181 ASIA PACIFIC: MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 182 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 183 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 184 ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 185 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 186 ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 187 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 188 ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 189 ASIA PACIFIC: MARKET, BY END USER, 2022–2029 (USD MILLION)
           8.4.2 CHINA
                    8.4.2.1 Low manufacturing cost of medicines to drive demand
                                TABLE 190 CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 191 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 192 CHINA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 193 CHINA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 194 CHINA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 195 CHINA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 196 CHINA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 197 CHINA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.4.3 JAPAN
                    8.4.3.1 Rising geriatric population to support market growth
                                TABLE 198 JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 199 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 200 JAPAN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 201 JAPAN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 202 JAPAN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 203 JAPAN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 204 JAPAN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 205 JAPAN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.4.4 INDIA
                    8.4.4.1 Increasing number of clinical trials to drive market
                                TABLE 206 INDIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 207 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 208 INDIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 209 INDIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 210 INDIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 211 INDIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 212 INDIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 213 INDIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.4.5 AUSTRALIA
                    8.4.5.1 Large number of research institutes make Australia favorable location for drug discovery
                                TABLE 214 AUSTRALIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 215 AUSTRALIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 216 AUSTRALIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 217 AUSTRALIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 218 AUSTRALIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 219 AUSTRALIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 220 AUSTRALIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 221 AUSTRALIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.4.6 SOUTH KOREA
                    8.4.6.1 Growth in clinical trial activities to propel market
                                TABLE 222 SOUTH KOREA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 223 SOUTH KOREA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 224 SOUTH KOREA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 225 SOUTH KOREA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 226 SOUTH KOREA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 227 SOUTH KOREA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 228 SOUTH KOREA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 229 SOUTH KOREA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.4.7 REST OF ASIA PACIFIC
                    TABLE 230 REST OF ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 231 REST OF ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 232 REST OF ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 233 REST OF ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 234 REST OF ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 235 REST OF ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 236 REST OF ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 237 REST OF ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
    8.5 LATIN AMERICA 
           8.5.1 LATIN AMERICA: RECESSION IMPACT
                    TABLE 238 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 239 LATIN AMERICA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 240 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 241 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 242 LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 243 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 244 LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 245 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 246 LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 247 LATIN AMERICA: MARKET, BY END USER, 2022–2029 (USD MILLION)
           8.5.2 BRAZIL
                    8.5.2.1 Rising adoption of emerging medical technologies to drive market
                                TABLE 248 BRAZIL: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 249 BRAZIL: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 250 BRAZIL: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 251 BRAZIL: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 252 BRAZIL: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 253 BRAZIL: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 254 BRAZIL: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 255 BRAZIL: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.5.3 MEXICO
                    8.5.3.1 Government initiatives and robust supply to drive market
                                TABLE 256 MEXICO: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 257 MEXICO: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 258 MEXICO: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 259 MEXICO: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 260 MEXICO: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 261 MEXICO: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 262 MEXICO: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 263 MEXICO: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.5.4 REST OF LATIN AMERICA
                    TABLE 264 REST OF LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 265 REST OF LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 266 REST OF LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 267 REST OF LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 268 REST OF LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 269 REST OF LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 270 REST OF LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 271 REST OF LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
    8.6 MIDDLE EAST & AFRICA 
           8.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
                    TABLE 272 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 273 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 274 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 275 MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 276 MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 277 MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 278 MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 279 MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 280 MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 281 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2022–2029 (USD MILLION)
           8.6.2 GCC
                    8.6.2.1 Supportive government initiatives to aid market growth
                                TABLE 282 GCC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 283 GCC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 284 GCC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 285 GCC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 286 GCC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 287 GCC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 288 GCC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 289 GCC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
           8.6.3 REST OF MIDDLE EAST & AFRICA
                    TABLE 290 REST OF MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 291 REST OF MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 292 REST OF MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 293 REST OF MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 294 REST OF MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 295 REST OF MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 296 REST OF MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 297 REST OF MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
 
9 COMPETITIVE LANDSCAPE (Page No. - 295)
    9.1 INTRODUCTION 
    9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 
          FIGURE 42 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: STRATEGIES ADOPTED
    9.3 REVENUE SHARE ANALYSIS 
          FIGURE 43 REVENUE ANALYSIS FOR KEY PLAYERS (2018–2022)
    9.4 MARKET SHARE ANALYSIS 
          FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
          TABLE 298 HEALTHCARE ANALYTICAL TESTING SERVICES INDUSTRY: DEGREE OF COMPETITION
    9.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 
           9.5.1 STARS
           9.5.2 PERVASIVE PLAYERS
           9.5.3 EMERGING LEADERS
           9.5.4 PARTICIPANTS
                    FIGURE 45 HEALTHCARE ANALYTICAL TESTING SERVICES INDUSTRY: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
           9.5.5 COMPANY FOOTPRINT
                    9.5.5.1 Overall footprint
                                FIGURE 46 HEALTHCARE ANALYTICAL TESTING SERVICES INDUSTRY: OVERALL FOOTPRINT
                    9.5.5.2 Service footprint
                                TABLE 299 HEALTHCARE ANALYTICAL TESTING SERVICES INDUSTRY: SERVICE FOOTPRINT
                    9.5.5.3 End-user footprint
                                TABLE 300 HEALTHCARE ANALYTICAL TESTING SERVICES INDUSTRY: END-USER FOOTPRINT
                    9.5.5.4 Regional footprint
                                TABLE 301 HEALTHCARE ANALYTICAL TESTING SERVICES INDUSTRY: REGIONAL FOOTPRINT
    9.6 COMPANY EVALUATION MATRIX: START-UPS/SMES 
           9.6.1 PROGRESSIVE COMPANIES
           9.6.2 DYNAMIC COMPANIES
           9.6.3 RESPONSIVE COMPANIES
           9.6.4 STARTING BLOCKS
                    FIGURE 47 HEALTHCARE ANALYTICAL TESTING SERVICES INDUSTRY: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
           9.6.5 COMPETITIVE BENCHMARKING
                    TABLE 302 HEALTHCARE ANALYTICAL TESTING SERVICES INDUSTRY: DETAILED LIST OF KEY START-UPS/SMES
                    TABLE 303 HEALTHCARE ANALYTICAL TESTING SERVICES INDUSTRY: COMPETITIVE BENCHMARKING OF START-UPS/SMES
    9.7 VALUATION AND FINANCIAL METRICS OF HEALTHCARE ANALYTICAL TESTING SERVICE VENDORS 
          FIGURE 48 EV/EBITDA OF KEY VENDORS
    9.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 
          FIGURE 49 BRAND/PRODUCT COMPARATIVE ANALYSIS OF KEY PLAYERS, BY SERVICE TYPE
           9.8.1 EUROFINS SCIENTIFIC
           9.8.2 WUXI APPTEC
           9.8.3 CHARLES RIVER LABORATORIES
           9.8.4 SGS S.A.
           9.8.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
    9.9 COMPETITIVE SCENARIO 
           9.9.1 SERVICE LAUNCHES
                    TABLE 304 HEALTHCARE ANALYTICAL TESTING SERVICES INDUSTRY: SERVICE LAUNCHES, JANUARY 2020–MARCH 2024
           9.9.2 DEALS
                    TABLE 305 HEALTHCARE ANALYTICAL TESTING SERVICES INDUSTRY: DEALS, JANUARY 2020–MARCH 2024
                    TABLE 306 HEALTHCARE ANALYTICAL TESTING SERVICES INDUSTRY: EXPANSIONS, JANUARY 2020–MARCH 2024
 
10 COMPANY PROFILES (Page No. - 318)
     10.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             10.1.1 EUROFINS SCIENTIFIC
                        TABLE 307 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
                        FIGURE 50 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
                        TABLE 308 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 309 EUROFINS SCIENTIFIC: DEALS
             10.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS
                        TABLE 310 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
                        FIGURE 51 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
                        TABLE 311 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 312 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS
                        TABLE 313 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS
             10.1.3 WUXI APPTEC
                        TABLE 314 WUXI APPTEC: COMPANY OVERVIEW
                        FIGURE 52 WUXI APPTEC: COMPANY SNAPSHOT (2022)
                        TABLE 315 WUXI APPTEC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 316 WUXI APPTEC: SERVICE LAUNCHES
                        TABLE 317 WUXI APPTEC: DEALS
                        TABLE 318 WUXI APPTEC: EXPANSIONS
             10.1.4 CHARLES RIVER LABORATORIES
                        TABLE 319 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
                        FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)
                        TABLE 320 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 321 CHARLES RIVER LABORATORIES: SERVICE LAUNCHES
                        TABLE 322 CHARLES RIVER LABORATORIES: DEALS
             10.1.5 SGS S.A.
                        TABLE 323 SGS S.A.: COMPANY OVERVIEW
                        FIGURE 54 SGS S.A.: COMPANY SNAPSHOT (2023)
                        TABLE 324 SGS S.A.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 325 SGS S.A.: DEALS
                        TABLE 326 SGS S.A.: OTHER DEVELOPMENTS
             10.1.6 THERMO FISHER SCIENTIFIC INC.
                        TABLE 327 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 55 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
                        TABLE 328 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 329 THERMO FISHER SCIENTIFIC INC.: DEALS
                        TABLE 330 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS
             10.1.7 MEDPACE, INC.
                        TABLE 331 MEDPACE, INC.: COMPANY OVERVIEW
                        FIGURE 56 MEDPACE, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 332 MEDPACE, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
             10.1.8 SARTORIUS AG
                        TABLE 333 SARTORIUS AG: COMPANY OVERVIEW
                        FIGURE 57 SARTORIUS AG: COMPANY SNAPSHOT (2022)
                        TABLE 334 SARTORIUS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 335 SARTORIUS AG: DEALS
             10.1.9 INTERTEK GROUP PLC
                        TABLE 336 INTERTEK GROUP PLC: COMPANY OVERVIEW
                        FIGURE 58 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2022)
                        TABLE 337 INTERTEK GROUP PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 338 INTERTEK GROUP PLC: DEALS
                        TABLE 339 INTERTEK GROUP PLC: EXPANSIONS
             10.1.10 MERCK KGAA
                        TABLE 340 MERCK KGAA: COMPANY OVERVIEW
                        FIGURE 59 MERCK KGAA: COMPANY SNAPSHOT (2022)
                        TABLE 341 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 342 MERCK KGAA: SERVICE LAUNCHES
                        TABLE 343 MERCK KGAA: DEALS
                        TABLE 344 MERCK KGAA: EXPANSIONS
                        TABLE 345 MERCK KGAA: OTHER DEVELOPMENTS
             10.1.11 SOURCE BIOSCIENCE
                        TABLE 346 SOURCE BIOSCIENCE: COMPANY OVERVIEW
                        FIGURE 60 SOURCE BIOSCIENCE: COMPANY SNAPSHOT (2022)
                        TABLE 347 SOURCE BIOSCIENCE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 348 SOURCE BIOSCIENCE: SERVICE LAUNCHES
                        TABLE 349 SOURCE BIOSCIENCE: EXPANSIONS
             10.1.12 ICON PLC
                        TABLE 350 ICON PLC: COMPANY OVERVIEW
                        FIGURE 61 ICON PLC: COMPANY SNAPSHOT (2022)
                        TABLE 351 ICON PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 352 ICON PLC: DEALS
             10.1.13 ALS
                        TABLE 353 ALS: COMPANY OVERVIEW
                        FIGURE 62 ALS: COMPANY SNAPSHOT (2022)
                        TABLE 354 ALS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 355 ALS: DEALS
             10.1.14 FRONTAGE LABORATORIES, INC.
                        TABLE 356 FRONTAGE LABORATORIES, INC.: COMPANY OVERVIEW
                        FIGURE 63 FRONTAGE LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 357 FRONTAGE LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 358 FRONTAGE LABORATORIES, INC.: DEALS
                        TABLE 359 FRONTAGE LABORATORIES, INC.: OTHER DEVELOPMENTS
             10.1.15 STERIS
                        TABLE 360 STERIS: COMPANY OVERVIEW
                        FIGURE 64 STERIS: COMPANY SNAPSHOT (2023)
                        TABLE 361 STERIS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
             10.1.16 IQVIA INC.
                        TABLE 362 IQVIA INC.: COMPANY OVERVIEW
                        FIGURE 65 IQVIA INC.: COMPANY SNAPSHOT (2023)
                        TABLE 363 IQVIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 364 IQVIA INC.: OTHER DEVELOPMENTS
             10.1.17 ELEMENT MATERIALS TECHNOLOGY
                        TABLE 365 ELEMENT MATERIALS TECHNOLOGY: COMPANY OVERVIEW
                        TABLE 366 ELEMENT MATERIALS TECHNOLOGY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 367 ELEMENT MATERIALS TECHNOLOGY: SERVICE LAUNCHES
                        TABLE 368 ELEMENT MATERIALS TECHNOLOGY: DEALS
                        TABLE 369 ELEMENT MATERIALS TECHNOLOGY: EXPANSIONS
             10.1.18 PACE ANALYTICAL SERVICES
                        TABLE 370 PACE ANALYTICAL SERVICES: COMPANY OVERVIEW
                        TABLE 371 PACE ANALYTICAL SERVICES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 372 PACE ANALYTICAL SERVICES: DEALS
                        TABLE 373 PACE ANALYTICAL SERVICES: OTHER DEVELOPMENTS
             10.1.19 ALMAC GROUP
                        TABLE 374 ALMAC GROUP: COMPANY OVERVIEW
                        TABLE 375 ALMAC GROUP: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 376 ALMAC GROUP: SERVICE LAUNCHES
                        TABLE 377 ALMAC GROUP: EXPANSIONS
             10.1.20 PHARMARON
                        TABLE 378 PHARMARON: COMPANY OVERVIEW
                        TABLE 379 PHARMARON: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 380 PHARMARON: DEALS
     10.2 OTHER PLAYERS 
             10.2.1 SYNEOS HEALTH
                        TABLE 381 SYNEOS HEALTH: COMPANY OVERVIEW
             10.2.2 PAREXEL INTERNATIONAL (MA) CORPORATION
                        TABLE 382 PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW
             10.2.3 LGC LIMITED
                        TABLE 383 LGC LIMITED: COMPANY OVERVIEW
             10.2.4 CELERION
                        TABLE 384 CELERION: COMPANY OVERVIEW
             10.2.5 BIOAGILYTIX
                        TABLE 385 BIOAGILYTIX: COMPANY OVERVIEW
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
11 APPENDIX (Page No. - 400)
     11.1 DISCUSSION GUIDE 
     11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     11.3 CUSTOMIZATION OPTIONS 
     11.4 RELATED REPORTS 
     11.5 AUTHOR DETAILS 

This research study involved the extensive use of both primary and secondary sources. It involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.

Secondary Research

This research study involved the wide use of secondary sources, directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, white papers, and companies’ house documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the Analytical Testing Services Market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply side and demand side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the Analytical Testing Services Market. Primary sources from the demand side included researchers, lab technicians, reagent suppliers, purchase managers etc,  and stakeholders in corporate & government bodies.

A breakdown of the primary respondents is provided below:

Healthcare Analytical Testing Services Market Size, and Share

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue, as of 2020: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the Analytical Testing Services Market was arrived at after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.

Healthcare Analytical Testing Services Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

The size of the Analytical Testing Service Market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as given below:

  • Shares of leading players in the Analytical Testing Services Market were gathered from secondary sources to the extent available. In some instances, shares of Analytical Testing Services have been ascertained after a detailed analysis of various parameters, including Service portfolios, market positioning, selling price, and geographic reach & strength.
  • Individual shares or revenue estimates were validated through interviews with experts.

The total revenue in the Analytical Testing Services Market was determined by extrapolating the Market share data of major companies.

Global Analytical Testing Services Market  Size: Top-Down Approach

Healthcare Analytical Testing Services Market Size, and Share

Market Definition

Healthcare analytical testing services are specifically utilized by the healthcare industry, particularly, pharmaceutical, biopharmaceutical, and medical device companies, to streamline the various stages of drug discovery and development as well as the medical device testing process.

Key Stakeholders

  • Healthcare Analytical Testing Service Providers
  • Pharmaceutical & Biopharmaceutical Companies
  • Biotechnology Companies
  • Bioanalytical Testing Service Providers
  • Environmental Testing Service Providers
  • Contract Research Organizations (CROs)
  • Medical Device Manufacturing Companies
  • Cosmetic Companies
  • Nutraceutical Companies
  • Forensic Laboratories
  • Academic Universities
  • Research Institutes
  • Research Laboratories
  • Government Associations
  • Market Research And Consulting Firms
  • Venture Capitalists And Investors

Objectives of the Study

  • To define, describe, and forecast the healthcare analytical testing services market based on type, end user, and region
  • To provide detailed information about the major factors influencing the market growth (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall healthcare analytical testing services market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the healthcare analytical testing services market in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their market shares and core competencies in the healthcare analytical testing services market
  • To track and analyze competitive developments such as partnerships, expansions, acquisitions, collaborations, service launches, agreements, and other developments in the healthcare analytical testing services market
  • To benchmark players within the healthcare analytical testing services market using the Company Evaluation Quadrant framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and service offerings

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • Further breakdown of the Rest of Europe Analytical Testing Services Market  into Denmark, Norway, and others
  • Further breakdown of the Rest of Asia Pacific Analytical Testing Services Market  into Vietnam, New Zealand, and others
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
AST 4341
Published ON
Apr, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Healthcare Analytical Testing Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
knowledgestore logo

Hold On!

Want to explore hidden markets that can drive new revenue in Healthcare Analytical Testing Services Market?

Find Hidden Markets
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status
Website Feedback